News Biogen shares up after strong launch for rare disease drug US insurers are covering the treatment, despite high price.
News After attracting star CEO Hung, Axovant looks to raise $125m Axovant Sciences is maintaining its momentum following the appointment of star biotech leader David Hung earlier this week with a new $125 million share offering.
News Merck's failure casts gloom over remaining BACE Alzheimer's ... But trial in patients in early stage of the disease continues.
News OECD calls for 'rebalancing of power' in drug price negotiat... Health systems should fund more treatments for chronic diseases, says EFPIA
News New Lilly CEO wields axe after Alzheimer's failure David Ricks revamps organisation after trial disappointment.
News AI specialists Enveda and Basecamp rake in the cash AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
